LINK . SPRINGER . COM {}

Detected CMS Systems:

Pivotx (1 occurrences)

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Link.springer.com Make Money
Keywords
Topics
Questions
Schema
External Links
Analytics And Tracking
Libraries
CDN Services

We are analyzing https://link.springer.com/article/10.1007/s10549-011-1919-y.

Title:
A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer | Breast Cancer Research and Treatment
Description:
Bevacizumab in combination with chemotherapy increases progression-free survival (PFS), but not overall survival when compared to chemotherapy alone in the treatment of metastatic breast cancer (MBC). Recently in November, 2011 the Food and drug administration revoked approval of bevacizumab in combination with paclitaxel for the treatment of MBC. The European Medicines Agency, in contrast, maintained its approval of bevacizumab in MBC. While neither agency considers health economics in their decision-making process, one of the greatest challenges in oncology practice today is to reconcile hard-won small incremental clinical benefits with exponentially rising costs. To inform policy-makers in the US, this study aimed to assess the cost-effectiveness of bevacizumab/paclitaxel in MBC, from a payer perspective. We created a decision analytical model using efficacy and adverse events data from the ECOG 2100 trial. Health utilities were derived from available literature. Costs were obtained from the Center for Medicare Services Drug Payment Table and Physician Fee Schedule and are represented in 2010 US dollars. Quality-adjusted life-years (QALY) and incremental cost-effectiveness ratio (ICER) were calculated. Sensitivity analyses were performed. Bevacizumab added 0.49 years of PFS and 0.135 QALY with an incremental cost of $100,300, and therefore a cost of $204,000 per year of PFS gained and an ICER of $745,000 per QALY. The main drivers of the model were drug acquisition cost, PFS, and health utility values. Using a threshold of $150,000/QALY, drug price would have to be reduced by nearly 80% or alternatively PFS increased by 10 months to make bevacizumab cost-effective. The results of the model were robust in sensitivity analyses. Bevacizumab plus paclitaxel is not cost-effective in treating MBC. Value-based pricing and the development of biomarkers to improve patient selection are needed to better define the role of the drug in this population.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Science
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Link.springer.com operates using PIVOTX.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

cancer, bevacizumab, breast, article, treatment, metastatic, drug, research, paclitaxel, mbc, pubmed, google, scholar, privacy, cookies, combination, firstline, lopes, pfs, approval, health, qaly, cas, content, analysis, data, publish, search, december, montero, gilberto, cost, access, oncol, miami, information, log, journal, costbenefit, patients, avancha, stefan, glück, chemotherapy, economics, incremental, model, discover, society, recurrent,

Topics {✒️}

gov/downloads/newsevents/newsroom/ucm280546 month download article/chapter american cancer society uk/newsroom/pressreleases/bevacizumabformetastaticbreastcancer cost-benefit analysis incremental cost-effectiveness ratio advanced/metastatic recurrent nonsquamous metastatic breast cancer quality-adjusted life-years breast cancer indication health state utilities health utility values make bevacizumab cost-effective privacy choices/manage cookies improve patient selection line therapy full article pdf drug acquisition cost received research funding kiran avancha european medicines agency oncology practice today decision-making process physician fee schedule cohen mh miami miller school conditions privacy policy adverse events data inform policy-makers european economic area high-income countries phase iii study phase iii trial check access curr oncol rep instant access accepting optional cookies health utilities exponentially rising costs incremental cost decision analytical model article montero alternatively pfs increased usage analysis gilberto lopes journal finder publish colorectal cancer usa alberto article log author information authors

Questions {❓}

Montero AJ, Escobar M, Lopes G, Gluck S, Vogel C (2011) Bevacizumab in the treatment of metastatic breast cancer: friend or foe?
Will Antibody Biosimilars See the Light of Day?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer
         description:Bevacizumab in combination with chemotherapy increases progression-free survival (PFS), but not overall survival when compared to chemotherapy alone in the treatment of metastatic breast cancer (MBC). Recently in November, 2011 the Food and drug administration revoked approval of bevacizumab in combination with paclitaxel for the treatment of MBC. The European Medicines Agency, in contrast, maintained its approval of bevacizumab in MBC. While neither agency considers health economics in their decision-making process, one of the greatest challenges in oncology practice today is to reconcile hard-won small incremental clinical benefits with exponentially rising costs. To inform policy-makers in the US, this study aimed to assess the cost-effectiveness of bevacizumab/paclitaxel in MBC, from a payer perspective. We created a decision analytical model using efficacy and adverse events data from the ECOG 2100 trial. Health utilities were derived from available literature. Costs were obtained from the Center for Medicare Services Drug Payment Table and Physician Fee Schedule and are represented in 2010 US dollars. Quality-adjusted life-years (QALY) and incremental cost-effectiveness ratio (ICER) were calculated. Sensitivity analyses were performed. Bevacizumab added 0.49 years of PFS and 0.135 QALY with an incremental cost of $100,300, and therefore a cost of $204,000 per year of PFS gained and an ICER of $745,000 per QALY. The main drivers of the model were drug acquisition cost, PFS, and health utility values. Using a threshold of $150,000/QALY, drug price would have to be reduced by nearly 80% or alternatively PFS increased by 10 months to make bevacizumab cost-effective. The results of the model were robust in sensitivity analyses. Bevacizumab plus paclitaxel is not cost-effective in treating MBC. Value-based pricing and the development of biomarkers to improve patient selection are needed to better define the role of the drug in this population.
         datePublished:2011-12-27T00:00:00Z
         dateModified:2011-12-27T00:00:00Z
         pageStart:747
         pageEnd:751
         sameAs:https://doi.org/10.1007/s10549-011-1919-y
         keywords:
            Breast cancer
            Cost-benefit analysis
            Pharmacoeconomics
            Bevacizumab
            Economics
            Metastatic breast cancer
            QALY
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1919-y/MediaObjects/10549_2011_1919_Fig1_HTML.gif
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:132
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Alberto J. Montero
               affiliation:
                     name:University of Miami Sylvester Comprehensive Cancer Center
                     address:
                        name:Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kiran Avancha
               affiliation:
                     name:University of Miami Miller School of Medicine Office of Research
                     address:
                        name:University of Miami Miller School of Medicine Office of Research, Miami, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Stefan Glück
               affiliation:
                     name:University of Miami Sylvester Comprehensive Cancer Center
                     address:
                        name:Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Gilberto Lopes
               affiliation:
                     name:Johns Hopkins Singapore International Medical Centre and Johns Hopkins University School of Medicine
                     address:
                        name:Johns Hopkins Singapore International Medical Centre and Johns Hopkins University School of Medicine, Singapore, Singapore
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer
      description:Bevacizumab in combination with chemotherapy increases progression-free survival (PFS), but not overall survival when compared to chemotherapy alone in the treatment of metastatic breast cancer (MBC). Recently in November, 2011 the Food and drug administration revoked approval of bevacizumab in combination with paclitaxel for the treatment of MBC. The European Medicines Agency, in contrast, maintained its approval of bevacizumab in MBC. While neither agency considers health economics in their decision-making process, one of the greatest challenges in oncology practice today is to reconcile hard-won small incremental clinical benefits with exponentially rising costs. To inform policy-makers in the US, this study aimed to assess the cost-effectiveness of bevacizumab/paclitaxel in MBC, from a payer perspective. We created a decision analytical model using efficacy and adverse events data from the ECOG 2100 trial. Health utilities were derived from available literature. Costs were obtained from the Center for Medicare Services Drug Payment Table and Physician Fee Schedule and are represented in 2010 US dollars. Quality-adjusted life-years (QALY) and incremental cost-effectiveness ratio (ICER) were calculated. Sensitivity analyses were performed. Bevacizumab added 0.49 years of PFS and 0.135 QALY with an incremental cost of $100,300, and therefore a cost of $204,000 per year of PFS gained and an ICER of $745,000 per QALY. The main drivers of the model were drug acquisition cost, PFS, and health utility values. Using a threshold of $150,000/QALY, drug price would have to be reduced by nearly 80% or alternatively PFS increased by 10 months to make bevacizumab cost-effective. The results of the model were robust in sensitivity analyses. Bevacizumab plus paclitaxel is not cost-effective in treating MBC. Value-based pricing and the development of biomarkers to improve patient selection are needed to better define the role of the drug in this population.
      datePublished:2011-12-27T00:00:00Z
      dateModified:2011-12-27T00:00:00Z
      pageStart:747
      pageEnd:751
      sameAs:https://doi.org/10.1007/s10549-011-1919-y
      keywords:
         Breast cancer
         Cost-benefit analysis
         Pharmacoeconomics
         Bevacizumab
         Economics
         Metastatic breast cancer
         QALY
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1919-y/MediaObjects/10549_2011_1919_Fig1_HTML.gif
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:132
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Alberto J. Montero
            affiliation:
                  name:University of Miami Sylvester Comprehensive Cancer Center
                  address:
                     name:Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kiran Avancha
            affiliation:
                  name:University of Miami Miller School of Medicine Office of Research
                  address:
                     name:University of Miami Miller School of Medicine Office of Research, Miami, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Stefan Glück
            affiliation:
                  name:University of Miami Sylvester Comprehensive Cancer Center
                  address:
                     name:Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Gilberto Lopes
            affiliation:
                  name:Johns Hopkins Singapore International Medical Centre and Johns Hopkins University School of Medicine
                  address:
                     name:Johns Hopkins Singapore International Medical Centre and Johns Hopkins University School of Medicine, Singapore, Singapore
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:132
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Miami Sylvester Comprehensive Cancer Center
      address:
         name:Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, USA
         type:PostalAddress
      name:University of Miami Miller School of Medicine Office of Research
      address:
         name:University of Miami Miller School of Medicine Office of Research, Miami, USA
         type:PostalAddress
      name:University of Miami Sylvester Comprehensive Cancer Center
      address:
         name:Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, USA
         type:PostalAddress
      name:Johns Hopkins Singapore International Medical Centre and Johns Hopkins University School of Medicine
      address:
         name:Johns Hopkins Singapore International Medical Centre and Johns Hopkins University School of Medicine, Singapore, Singapore
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Alberto J. Montero
      affiliation:
            name:University of Miami Sylvester Comprehensive Cancer Center
            address:
               name:Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, USA
               type:PostalAddress
            type:Organization
      name:Kiran Avancha
      affiliation:
            name:University of Miami Miller School of Medicine Office of Research
            address:
               name:University of Miami Miller School of Medicine Office of Research, Miami, USA
               type:PostalAddress
            type:Organization
      name:Stefan Glück
      affiliation:
            name:University of Miami Sylvester Comprehensive Cancer Center
            address:
               name:Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, USA
               type:PostalAddress
            type:Organization
      name:Gilberto Lopes
      affiliation:
            name:Johns Hopkins Singapore International Medical Centre and Johns Hopkins University School of Medicine
            address:
               name:Johns Hopkins Singapore International Medical Centre and Johns Hopkins University School of Medicine, Singapore, Singapore
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, USA
      name:University of Miami Miller School of Medicine Office of Research, Miami, USA
      name:Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, USA
      name:Johns Hopkins Singapore International Medical Centre and Johns Hopkins University School of Medicine, Singapore, Singapore
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(54)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.11s.